Bleeding disorders, such as hemophilia and von Willebrand disease (VWD), are caused by missing or deficient blood clotting factors.1
Clotting factors are specialized proteins that circulate in the blood to control bleeding. These factors work together in a chain reaction to form clots. If even one of these factors is missing or deficient, clotting may be difficult.1
There are many types of factor deficiencies but the most common among these rare diseases are2,3:
Many clotting factors are designated by Roman numerals.1
Bleeding disorders are conditions that, for the most part, are inherited from an affected parent.2,4 However, sometimes bleeding disorders are the result of a spontaneous genetic mutation rather than genetic inheritance, and other times they are developed later in life.2,5 Regardless, it’s nobody’s fault for having or passing along a bleeding disorder gene. While bleeding disorders cannot be prevented, they can be treated and managed.6-8
Be among the first to get news and information from the Bleeding Disorders Community.
No, thanks
Takeda has been closely monitoring the news surrounding COVID-19. Our highest priority is the health and safety of our community during this uncertain time.
We are taking steps to help ensure the community’s safety including postponing upcoming educational events such as our HELLO TALK® programs. We appreciate your understanding and we will be regularly updating our events on our website.
A global pandemic such as COVID-19 can cause alarm but we urge you to consult with your healthcare provider to discuss questions regarding your condition and COVID-19. In addition, the CDC (Centers for Disease Control and Prevention) website includes information on things like COVID-19 symptoms, how to protect yourself and others from the virus, and who may be at higher risk for complications due to the virus. The National Hemophilia Foundation and the Hemophilia Federation of America are also helpful resources for patients with bleeding disorders and caregivers.
For those of you who are currently on Takeda treatments, based on current assessments of our global supply chain, we do not anticipate any potential supply disruption in the near-term due to the Coronavirus outbreak. Longer-term, it is not yet possible to predict precisely what the impact may be on individual products. We will continue to monitor the situation as it evolves and take all necessary actions in an effort to ensure supply continuity for the people we serve. Rest assured, we will keep patient advocacy organizations and health care providers informed of any material changes in status.
If you have been prescribed a Takeda therapy and have questions, you can call our Hematology Support Center at 888-229-8379 Monday through Friday from 8:30 AM to 8:00 PM.
We are in this together with you.
